Anti-uPAR, clone 2G10 ZooMAb�

Application

Inhibits Activity/Function: A representative lot of this antibody inhibited the invasion of MDA-MB-231 cells (Harel, E., et al., 2014 UCSF Scientific Poster).Flow Cytometry Analysis: 0.1 µg from a representative lot detected uPAR in one million SH-SY5Y cells.Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected uPAR in human lung cancer tissue sections.Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected uPAR in HT1080 cells.Note: Actual optimal working dilutions must be determined by the end user as specimens and experimental conditions may vary.

Anti-uPAR, clone 2G10 ZooMAb, Cat. No. ZRB1224, is a Rabbit monoclonal antibody that targets uPAR and has been tested for use in Flow Cytometry, Immunocytochemistry, Immunohistochemistry, Inhibition Assay, and Western Blotting.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

ZooMAb antibodies represent an entirely new generation of recombinant monoclonal antibodies.Each ZooMAb antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb antibodies are reliably available and ready to ship when you need them.Learn more about ZooMAb here.

Immunogen

A recombinant fragment corresponding the first 277 amino acids from human Urokinase plasminogen activator surface receptor (uPAR).

Legal Information

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Physical form

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

Reconstitution

300 µg/mL after reconstitution at 25 µL. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Specificity

Clone 2G10 is a ZooMAb rabbit recombinant monoclonal antibody that specifically detects human Urokinase plasminogen activator surface receptor (uPAR).

Storage and Stability

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

Target description

Urokinase plasminogen activator surface receptor (UniProt: Q03405; also known as U-PAR, uPAR. Monocyte activation antigen Mo3, CD87) is encoded by the PLAUR (also known as MO3, UPAR) gene (Gene ID: 5329) in human. uPAR is a GPI-anchored cell membrane receptor for urokinase plasminogen activator (uPA), an enzyme responsible for the activation of plasmin and degradation of extracellular matrix components. It is also a subject to negative-feedback regulation by U-PA, which cleaves it into an inactive form. uPAR is synthesized with a signal peptide (aa 1-22) and a propeptide (aa 306-335), which are subsequently cleaved off to produce the mature form. The mature form has three homologous domains known as DI, DII, and DIII. Higher expression of uPAR has been reported in many human cancers, including non-small cell lung cancer and colorectal cancer and it correlates with a poor prognosis and early invasion and metastasis. uPAR, through integrins interaction, is reported to play a crucial role in activating Src, FAK and paxillin, which are considered as critical mediators of cell migration. In addition, via its interaction with chemotaxis receptors for fMet-lleu-Phe, it mediates both uPA and fMLF-dependent cell migration. uPAR has also been implicated in cross-talk with EGFR, which mediates the shift from tumor cell dormancy to proliferation. This ZooMAb recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Di Mauro, C., et al. (2017). Sci. Rep. 7; Article 9388).